Results from one of the CDT’s recent studies showed that by using closed-loop control 24/7
median time at less than 70 mg/dL decreased from 4.1% at baseline to 1.7% (P < .001), median time in target increased from 65% to 73% (P < .001), median time at more than 180 mg/dL decreased from 32% to 25% (P = .001) and median coefficient of variation decreased from 38% to 34% (P < .001).
Tags: artificial pancreas, clinical trial, results